Suppression of the intrinsic apoptosis pathway by sinaptic activity by Léveillé, Frédéric et al.
Cellular/Molecular
Suppression of the Intrinsic Apoptosis Pathway by Synaptic
Activity
Fre´de´ric Le´veille´,1* Sofia Papadia,1* Michael Fricker,2* Karen F. S. Bell,1 Francesc X. Soriano,1Marc-Andre´ Martel,1
Clare Puddifoot,1Marlen Habel,3David J. Wyllie,1 Chrysanthy Ikonomidou,3,4 Aviva M. Tolkovsky,2
and Giles E. Hardingham1
1Centre for Integrative Physiology, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom, 2Department of Biochemistry, University of Cambridge,
Cambridge CB2 1QW, United Kingdom, 3Department of Pediatric Neurology, Technical University Dresden, 01307 Dresden, Germany, and 4Department of
Neurology andWaisman Center, University of Wisconsin, Madison, Wisconsin 53705
Synaptic activity promotes resistance to diverse apoptotic insults, the mechanism behind which is incompletely understood. We show
here that a coordinateddownregulationof core components of the intrinsic apoptosis pathwaybyneuronal activity formsakeypart of the
underlying mechanism. Activity-dependent protection against apoptotic insults is associated with inhibition of cytochrome c release in
most but not all neurons, indicative of anti-apoptotic signaling both upstreamand downstreamof this step.We find that enhanced firing
activity suppresses expression of the proapoptotic BH3-only member gene Puma in a NMDA receptor-dependent, p53-independent
manner. Puma expression is sufficient to induce cytochrome c loss and neuronal apoptosis. Puma deficiency protects neurons against
apoptosis and also occludes the protective effect of synaptic activity, while blockade of physiological NMDA receptor activity in the
developing mouse brain induces neuronal apoptosis that is preceded by upregulation of Puma. However, enhanced activity can also
confer resistance to Puma-induced apoptosis, acting downstream of cytochrome c release. This mechanism is mediated by transcrip-
tional suppression of apoptosome components Apaf-1 and procaspase-9, and limiting caspase-9 activity, since overexpression of
procaspase-9 accelerates the rate of apoptosis in active neurons back to control levels. Synaptic activity does not exert further significant
anti-apoptotic effects downstreamof caspase-9 activation, since an inducible formof caspase-9 overrides the protective effect of synaptic
activity, despite activity-induced transcriptional suppression of caspase-3. Thus, suppression of apoptotic gene expression may syner-
gize with other activity-dependent events such as enhancement of antioxidant defenses to promote neuronal survival.
Introduction
The intrinsic apoptosis pathwaymediates the caspase-dependent
death of cells in response to intrinsic signals (Benn and Woolf,
2004; Meier and Vousden, 2007). This involves mitochondrial
permeability transition (MPT) and release of apoptotic factors
including cytochrome c and Smac/Diablo, controlled by the bal-
ance of pro- and anti-apoptotic members of the bcl-2 superfam-
ily (Youle and Strasser, 2008).Members of the BH3-only domain
subfamily promote mitochondrial release of apoptotic factors by
antagonizing anti-apoptoticmembers of the bcl-2 subfamily, and
facilitating the action of proapoptotic members of the Bax
subfamily. Released cytochrome c binds to Apaf-1 (apoptosis
protease activating factor), which oligomerizes and recruits
procaspase-9, which then becomes activated, forming the apop-
tosome (Riedl and Salvesen, 2007). Caspase-9 then proteolyti-
cally activates downstream effector caspases such as caspase-3
and -7.
In the developing nervous system, apoptosis is crucial for the
elimination of unwanted or inappropriately connected neurons
(Buss et al., 2006). However, pathological apoptosis can take
place following trauma such as oxidative stress, hypoxia/isch-
emia, and genotoxin exposure. Induction of neuronal apoptosis
can occur via upregulation of BH3-only genes such as Puma
(Wong et al., 2005; Wyttenbach and Tolkovsky, 2006; Kieran et
al., 2007; Steckley et al., 2007). In the mature nervous system,
neurons are less vulnerable to apoptosis, but it can still take place
following the aforementioned trauma. Apoptotic-like neuronal
death or the activation of apoptotic biochemical cascades (e.g.,
caspases) are proposed to be associated with certain neurodegen-
erative diseases, such as Alzheimer’s and Parkinson’s diseases
(Viswanath et al., 2001; Mattson, 2006; Ribe et al., 2008; Rohn
and Head, 2009), where the trigger may be oxidative stress, exci-
totoxins, or endoplasmic reticulum (ER) stress (Culmsee and
Landshamer, 2006; Halliwell, 2006).
Apoptosis is also a feature of acute injury, including in the
ischemic penumbra (Ray, 2006) and the pericontusional zone
followingmechanical trauma (Min˜ambres et al., 2008; Ribe et al.,
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2008). Given the relevance of apoptosis andmitochondrial integ-
rity to the development and pathophysiology of the CNS, it is
important to understand endogenous mechanisms that suppress
apoptosis, as this may lead to therapeutic targets and an under-
standing of pathological processes.
Survival of many neuronal types relies on physiological elec-
trical activity, as evidenced by the deleterious effects of blocking
activity in vivo and in vitro (Catsicas et al., 1992; Linden, 1994;
Mennerick and Zorumski, 2000). Activity-dependent intracellu-
lar Ca2 transients are important mediators of this neuroprotec-
tion, and the NMDA subtype of ionotropic glutamate receptors
(NMDARs) is a key source of such transients.While high levels of
NMDAR activity can be harmful, so too is blockade of normal
synaptic NMDAR activity (Hardingham, 2009), indicating a pro-
survival role for synaptic NMDARs. Neurons are particularly
vulnerable to NMDAR blockade-induced apoptosis during
postnatal development (Ikonomidou et al., 1999; Olney et al.,
2002). However, in the adult rat brain NMDAR antagonists can
also trigger neurodegeneration and exacerbate apoptosis induced
by an additional trauma (Olney et al., 1989; Horva´th et al., 1997;
Wozniak et al., 1998; Ikonomidou et al., 2000) and prevent sur-
vival of newborn neurons in the adult dentate gyrus (Tashiro et
al., 2006).
The exact molecular events that underlie the anti-apoptotic
effect of synaptic activity are incompletely understood. We re-
cently found that synaptic NMDAR activity boosts neuronal an-
tioxidant defenses via a coordinated program of antioxidant gene
transcription (Papadia et al., 2008). While changes in expression
of these genes contribute to activity-dependent resistance to ox-
idative stress-induced apoptosis, they do not account for all of it.
Synaptic activity can protect central neurons against a wide vari-
ety of apoptotic insults in vitro (Papadia et al., 2005). This raises
the possibility that this protection is mediated by a common
mechanism involving central components of the intrinsic apo-
ptosis pathway. Here we show that synaptic activity promotes the
transcriptional suppression of several key components of the core
apoptotic machinery, promoting resistance to diverse apoptotic
insults, including oxidative stress.
Materials andMethods
Neuronal cultures, stimulation, and the induction of apoptosis. Cortical
mouse neurons were cultured as described previously (Papadia et al.,
2008) at a density of between 9 and 13 104 neurons per cm2 fromE17.5
mice with Neurobasal growthmedium supplemented with B27 (Invitro-
gen). p53-null founder mice were obtained from Dr. Alan Clarke (Uni-
versity of Cardiff, Cardiff, UK) andwere extensively crossed into theCD1
background. Puma-null founder mice were obtained from Dr. Andreas
Strasser (TheWalter and ElizaHall Institute,Melbourne, VIC, Australia)
(Villunger et al., 2003). Stimulations of cultured neuronswere done in all
cases after a culturing period of 8–10 d during which cortical neurons
develop a network of processes, express functional NMDA-type and
AMPA/kainate-type glutamate receptors, and form synaptic contacts.
Our cultured neurons are 10–15% GABAergic (assessed by immunoflu-
orescence). Bursts of action potential firingwere induced by treatment of
neurons with 50 M bicuculline, and burst frequency was enhanced by
addition of 250M 4-aminopyridine (Hardingham et al., 2001).MK-801
(used at 10 M) was from Tocris Bioscience, TTX (at 2 M) and
4-aminopyridine from Calbiochem. Neurons were subjected to trophic
deprivation by transferring them from growth medium to a medium
containing 10% MEM (Invitrogen), 90% salt–glucose–glycine (SGG)
medium ((Bading et al., 1993); SGG: 114 mM NaCl, 0.219% NaHCO3,
5.292mMKCl, 1mMMgCl2, 2mMCaCl2, 10mMHEPES, 1mMglycine, 30
mM glucose, 0.5 mM sodium pyruvate, 0.1% Phenol Red; osmolarity 325
mOsm/L,(Papadia et al., 2005)). For this model, apoptosis was analyzed
after 72 h. Neurons were fixed and subjected to DAPI staining and cell
death quantified by counting (blind) the number of apoptotic nuclei as a
percentage of the total. Approximately 1500 cells were counted per treat-
ment, across 4 independent experiments (i.e., performed on separate
cultures). Morphologically, neurons subjected to trophic deprivation
show typical signs of apoptotic-like cell death (shrunken cell body and
large round chromatin clumps). Furthermore, death was blocked by the
pan-caspase inhibitor QVD-Oph (50 M) (Fig. 1A). Chemical inducers
of apoptosis were used as follows: staurosporine (Calbiochem, 100 nM),
9-cis-retinoic acid (Sigma, 5 M), okadaic acid (Calbiochem, 2 nM), and
hydrogen peroxide (Sigma, 100 M). Cell death in all cases was blocked
by pretreatment with QVD-Oph (50 M) [Fig. 1A and Papadia et al.
(2008)]. These inducers were applied to neurons for 24 h, after which the
percentage of apoptotic neurons was analyzed as described above.
In vivoMK-801 administration. Animal experiments were performed
in accordance with the guidelines of the University of Technology,
Dresden, Germany. Six-day-old (P6) male CD1 mice (Charles River)
received two (at 0 and 8h) consecutive intraperitoneal injections of saline
vehicle or the noncompetitive NMDA receptor antagonist dizocilpine
(MK-801, Tocris Bioscience) in a dose of 0.5 mg/kg per injection (10
ml/kg). Pups were exposed to MK-801 or vehicle for up to 12 h after the
first dose. The cingulate, retrosplenial, frontal, and parietal cortices were
rapidly collected, pooled, and snap-frozen in liquid nitrogen. Samples
were kept at 80°C until further processing. Total cellular RNA was
isolated by acidic phenol/chloroform extraction (Peqlab).
Caspase assays and inhibition. Cortical neurons plated in a 24-well
plate were incubated for 5 min in 150 l of PBS supplemented with
Triton X-100 0.5%. Lysates were further homogenized by pipetting. Fifty
microliters of the lysates were transferred in a 96-well plate containing 50
l of either Caspase-Glo 3/7 or Caspase-Glo 9 reagents (Promega) pre-
viously equilibrated at room temperature. As described in the manufac-
turer’s instructions, MG-132 was added in the Caspase-Glo 9 reagent to
reduce nonspecific background activity. Measurements were performed
on FLUOstar OPTIMA (BMG Labtech). Caspase activity was then nor-
malized to protein concentrationmeasured by bicinchoninic acid (BCA)
assay (Pierce Biotechnology) and expressed in fold induction compared
to the corresponding control. Where used, QVD-Oph (Merck Bio-
sciences) was used at 50 M.
Immunofluorescence and Western blotting. Immunofluorescence was
performed as described previously (Mckenzie et al., 2005). Pictures were
taken on a Leica AF6000 LX imaging system, with a DFC350 FX digital
camera. Primary antibodies used: Cytochrome c (1:500, PharMingen),
Puma (1:500, Prosci), anti-Smac/DIABLO (9H10, 1:100, Alexis). Anti-
body binding was visualized using biotinylated secondary antibody/Cy3-
conjugated streptavidin, or a Cy2 anti-mouse antibody. Nuclei were
counter-stained with DAPI. For Western blotting, total cell lysates were
boiled at 100°C for 5 min in 1.5 sample buffer (1.5 M Tris, pH 6.8;
glycerol 15%; SDS 3%; -mercaptoethanol 7.5%; bromophenol blue
0.0375%). Gel electrophoresis andWestern blotting were performed us-
ing Xcell Surelock system (Invitrogen) using precast gradient gels (4–
20%) according to themanufacturer’s instructions. The gels were blotted
onto PVDF membranes, which were then blocked for 1 h at room tem-
perature with 5% (w/v) nonfat dried milk in TBS with 0.1% Tween 20.
The membranes were then incubated at 4°C overnight with the pri-
mary antibodies diluted in blocking solution: Puma (1:500, Prosci),
Procaspase-9 (1:1000, Cell Signaling Technology), Apaf-1 (1:500, 13F11,
Alexis),-tubulin (1:100,000, Sigma). For visualization ofWestern blots,
HRP-based secondary antibodies were used followed by chemilumines-
cent detection on Kodak X-Omat film. Western blots were analyzed by
digitally scanning the blots, followed by densitometric analysis (ImageJ).
All analysis involved normalizing to a loading control -tubulin.
RNA isolation, RT-PCR, and qPCR.RNAwas isolated using theQiagen
RNeasy isolation reagents (including the optional DNase treatment) fol-
lowing passage of the cells through a QiaShredder column. For qPCR,
cDNAwas synthesized from 1–3g of RNA using the Stratascript QPCR
cDNA Synthesis kit (Stratagene) according to the manufacturer’s in-
structions. Briefly, the required amount of RNA (up to 3g) was diluted
in RNase-free water (up to 7 l final volume) and mixed on ice with 2
cDNA Synthesis master mix (10 l), random primers: oligo-dT primers
3:1 (total 2 l—200 ng) and either 1 l of RT/RNase block enzyme
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mixture (for RT reactions) or 1l of water (for no-RT control reactions).
Reactionmixturesweremixed and spundown and incubated for 2min at
25°C, 40 min at 42°C, and 5 min at 95°C. cDNA was stored at20°C.
Dilutions of this cDNA were subsequently used for real-time PCR
(cDNA equivalent to 6 ng of initial RNA per 15 l qPCR reaction for all
genes). qPCR was performed in anMx3000P QPCR System (Stratagene)
using Brilliant SYBRGreen QPCRMaster Mix (Stratagene) according to
the manufacturer’s instructions. Briefly, the required amount of tem-
plate was mixed on ice with 2 Brilliant SYBR Green Master Mix, for-
ward and reverse primers at 200 nM each final concentration, 30 nM final
concentration ROX passive reference dye, and water to the required
reaction volume. Technical replicates as well as no-template and no-RT
negative controls were included, and at least three biological replicates
were studied in each case. The sequences of the primers used are as
follows: Puma: F—5-CCT CAA CGC GCA GTA CG-3; R—5-TAG-
GCACCTAGTTGGGCTC-3; Apaf1: F—5-GAT GGT CCT TGC AGT
TGA C-3; R—5-GAC ATT CCA CAC CTT CAC C-3; Caspase 9:
F—5-GTG GAC ATT GGT TCT GGC-3;
R—5-GTT GAT GAT GAG GCA GTGG-3;
Caspase 3: F—5-TCT TCA TCA TTC AGG
CCT G-3; R—5-TGA ATT TCT CCA GGA
ATAGTAACC-3; GAPDH: F—5-GGGTGT
GAA CCA CGAGAA AT-3; R—5-CCT TCC
ACAATGCCAAAGTT-3; 18S rRNA: F—5-
GTGGAGCGATTTGTCTGGTT-3; R—5-
CAA GCT TATGACCCGCAC TT-3; Trp53:
F1—5-GAT GAC TGC CAT GGA GGAG-3;
R1—5-GAT CGT CCA TGC AGT GAGG-3.
The cycling program was 10 min at 95°C; 40
cycles of 30 s at 95°C, 40 s at 60°C with detec-
tion of fluorescence and 30 s at 72°C; 1 cycle
(for dissociation curve) of 1 min at 95°C and
30 s at 55°C with a ramp up to 30 s at 95°C
(ramp rate: 0.2°C/s) with continuous detection
of fluorescence on the 55–95°C ramp. The data
were analyzed using the MxPro QPCR analysis
software (Stratagene). Expression of the gene
of interest was normalized to GAPDH, a com-
monly used control. To confirm that nor-
malizing to GAPDH is not introducing any
systematic errors to our studies on activity-
dependent gene expression,wemeasured levels
of another commonly used control gene (18S
rRNA) compared to GAPDH under our dif-
ferent stimulation paradigms and found no
significant differences. Compared to unstimu-
lated neurons, GAPDH levels in MK-801-
treated neurons (normalized to 18S rRNA)
levels were 86  21% ( p  0.55, t test). In
neurons stimulated for 4 h with BiC/4-AP,
GAPDH levels (normalized to 18S rRNA) were
109 17% ( p 0.72, t test).
Transfection and following the fate of trans-
fected cells. Neurons were transfected at DIV8
using Lipofectamine 2000 (Invitrogen). Trans-
fection efficiency was 5%. 99% of eGFP-
expressing transfected neurons were NeuN
positive, and	1%were GFAP positive (Soriano
et al., 2008), confirming their neuronal iden-
tity. For the first set of neuronal viability assays,
peGFP was used to track the fate of transfected
neurons expressing the plasmid of interest
(Puma vs globin control vs Puma-
BH3). To
ensure that GFP-positive neuronswere also ex-
pressing the plasmid of interest, a favorable ra-
tio was used (peGFP: plasmid of interest, 1:2).
Coexpression at this ratio was confirmed in the
case of pRFP (Papadia et al., 2008). Where
used, siRNA was transfected at a final concen-
tration of 100 nM (Puma target sequence: CCU
GAU GCC CUC CGC UGU A). Dharmacon’s nontargeting siRNA #2
siRNA was used as control. Pictures of GFP-expressing neurons were
taken on a Leica AF6000 LX imaging system, with a DFC350 FX digital
camera. Using the automated cell-finder function within the Leica
AF6000 software, images of transfected neurons were taken at the
indicated intervals after transfection. Cell death at a particular time
point was assessed by counting the number of surviving GFP-positive
neurons. In the vast majority of cases, death was easily spotted as an
absence of a healthy GFP-expressing cell where one once was. In place
of the cell, there was in most cases (90%) evidence of death in the
form of fragmented neurites, fluorescent cell debris, and an apoptotic
nucleus (Papadia et al., 2008). This confirmed that the cells were
genuinely dying as opposed to more unlikely scenarios such as
quenching of eGFP fluorescence in a subpopulation of neurons. This
is also underlined by the fact that death measured by this technique is
blocked by caspase inhibitors (Papadia et al., 2008).
Figure 1. Neuroprotection afforded by synaptic activity. A, Synaptic activity protects neurons against inducers of apoptosis.
Mouse cortical neurons were treated in the presence or absence of the indicated compounds [BiC/4-AP: bicuculline (50M) plus
4-aminopyridine (250M) is labeledas “BiC” in figures];MK-801usedat 10Mhere and throughout. Thesedrugswere added16h
before the addition of inducers of apoptosis (staurosporine, 100 nM; retinoic acid, 5M; okadaic acid, 2 nM). QVD-Ophwas used at
50M and added 1 h before the addition of inducers of apoptosis. After a further 24 h, the neurons were fixed and levels of cell
death calculated. In the case of trophic deprivation, neuronswere subjected to 72h in trophically deprivedmedium in the presence
or absence of BiC, MK-801, or QVD-Oph. *p	 0.05 (compared to levels of death in the equivalent control condition); #p	 0.05
compared to levels of death in theBiC/4-AP-stimulatedneurons [two-wayANOVA followedbyFisher’s LSD test (n4)]. “Nodeath
stimulus” refers to neurons placed in standard transfection medium containing the insulin-transferrin-selenite supplement (tro-
phicmedium).B, Caspase-3/7 activationby apoptotic stimuli is suppressedby synapticNMDARactivity. For the trophic deprivation
model, neuronswere treatedwith the indicated drugs for 48 h in trophically deprivedmedium. For the staurosporine (STS)model,
neurons were treated with the indicated drugs for 16 h before treatment with staurosporine (100 nM) for a further 16 h. Control
condition is trophicmedium as described inA. Caspase-3/7 activity wasmeasured and normalized to protein levels ascertained by
BCA assay. *p 	 0.05, one-way ANOVA followed by Fisher’s LSD test here and elsewhere unless otherwise stated (n  4).
C, Synaptic NMDAR activity inhibits staurosporine-induced cytochrome c (Cyt c) release. Neuronswere treated as inA. Cytochrome
c immunofluorescent staining was performed 16 h after exposure to staurosporine. Asterisks highlight cells exhibiting diffuse
staining throughout the neuron, a transient state that precedes loss of staining and apoptosis. Thewhite arrows highlight neurons
where cytochrome c has been lost, but nuclear chromatin fragmentation has not taken place, indicative of protection downstream
of cytochrome c release. Pictures are representative of four independent experiments. Scale bar, 40m.D, Quantification of data
shown in C. For each condition,1500 cells were analyzed across four independent experiments. *p	 0.05 compared to control
condition (STS treated).
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For the experiments monitoring the effect of procaspase-9 expression
on neuronal apoptosis, neurons were transfected with peGFP plus either
control vector or a vector encoding procaspase-9 (Origene). Neurons
were immediately put in trophically deprived (TD)medium, and images
of transfected cells were taken at 24 h after transfection, when levels of
TD-induced death are very low. Images were then taken at 48 and 72 h
after transfection. For each combination of plasmid(s) and stimulation
condition, the fate of130–200 neurons was monitored over 4–6 inde-
pendent experiments.
Luciferase reporter assays. Firefly luciferase-based reporter gene con-
structs [Puma-Luc, Apaf1-Luc, and Casp9-Luc (Moroni et al., 2001;
Tsujimoto et al., 2005; Wu et al., 2005)] were transfected along with a
Renilla expression vector (pTK-RL). Neurons were stimulated (where
appropriate) 24 h after transfection. Luciferase assays were performed
using the Dual Glo assay kit (Promega) with Firefly luciferase-based
reporter gene activity normalized to the Renilla control (pTK-RL
plasmid) in all cases.
Statistical analysis, equipment, and settings. In all figures, the mean 
SEM is shown. Statistical testing involved a 2-tailed paired student t test.
For studies using multiple testing (e.g., the use of two pairs of siRNA, or
comparisons betweenmultiple deletion/mutant luciferase reporters con-
structs), we used a one-way ANOVA followed by Fisher’s LSD post hoc
test. For Western blots, we used chemiluminescent detection on Kodak
X-Omat film. Appropriate exposures were taken such that bands were
not saturated. For figure preparation of example Western blots, linear
adjustment of brightness/contrast was applied (Photoshop) equally
across the entire image, taking care to maintain some background inten-
sity. Pictures of transfected neurons were taken on a Leica AF6000 LX
imaging system, with a DFC350 FX digital camera. The DFC350 FX
digital camera is a monochrome camera, and so colored images (e.g., of
green fluorescent protein) essentially involve taking a black and white
image (using the appropriate filter set) and applying a color to the image
after capture. All luminescent assays were performed on a FLUOstar
OPTIMA (BMG Labtech). Light collection time and gain were set such
that counts were substantially lower than themaximum level collectable.
Results
Suppression of cytochrome c release, caspase activation, and
apoptosis by synaptic NMDAR activity
To analyze the molecular mechanisms involved in synaptic
activity-dependent neuroprotection, we recapitulated activity-
dependent neuroprotection in vitro using established models for
neuronal apoptosis (Papadia et al., 2005).We used an established
method of network disinhibition to enhance synaptic activity, by
applying the GABAA receptor antagonist bicuculline. This treat-
ment results in synchronized bursts of action potentials (APs)
that are associated with intracellular Ca2 transients dependent
on influx through NMDA receptors, as well as release from
internal stores and some influx through voltage-gated chan-
nels (Hardingham et al., 2001). The K channel antagonist
4-aminopyridine was coapplied with bicuculline to enhance
burst frequency (Hardingham et al., 2001) (hereafter BiC/4-AP).
BiC/4-AP treatment results in the protection ofmouse and rat
cortical neurons from apoptosis due to oxidative stress by en-
hancement of intrinsic antioxidant defenses (Papadia et al.,
2008). However, we wanted to know whether anti-apoptotic
mechanisms also contribute to activity-dependent neuroprotec-
tion, in addition to antioxidant mechanisms. To test the general
anti-apoptotic action of BiC/4-AP-induced activity, we used a
range of different insults: trophic deprivation, staurosporine,
retinoic acid, and okadaic acid, which all induce apoptosis which
is blocked by the pan-caspase inhibitor QVD-Oph [Fig. 1A and
Papadia et al. (2008)].We observed that BiC/4-AP-induced burst
activity protected mouse cortical neurons against all of these in-
sults (Fig. 1A), consistent with studies using other cell types such
as rat hippocampal neurons (Hardingham et al., 2002; Papadia et
al., 2005).
These apoptosis inducers are widely used activators of intrin-
sic apoptosis involving cytochrome c release and caspase activa-
tion and operate via multiple effects that contribute to cell death.
However, a common theme in these (and inducers in general) is
to alter the balance in the expression and/or activity of pro- and
anti-apoptotic bcl2 family members in favor of the proapoptotic
members ((Fujimura et al., 2003; Chen et al., 2005; Akhtar et al.,
2006; Mouratidis et al., 2006; Jayaraj et al., 2009; Roy et al., 2009)
and references therein). The observation that the anti-apoptotic
effects of neuronal activity are not insult-specific (Fig. 1A) points
to the existence of activity-induced events that target fundamen-
tal parts of the intrinsic apoptosis pathway (see below).
The efficacy of this protection, quantified by assessing nuclear
morphology, was confirmed electrophysiologically. Focusing on
the BiC/4-AP-treated neurons that were exposed to an ordinarily
toxic dose of staurosporine (100 nM), we injected current into the
rescued cells (with 300ms pulses at 1Hz) to bring them to thresh-
old. In current clamp configuration, all surviving cells studied
fired action potential bursts when depolarized beyond40 mV,
as was observedwith non-staurosporine-treated neurons (see ex-
amples in supplemental Fig. S1, available at www.jneurosci.org as
supplemental material). The protection afforded by BiC/4-AP
treatment was reduced by the coapplication of MK-801, demon-
strating the importance of NMDAR activity in AP burst activity-
evoked neuroprotective signaling, as shown previously (Papadia
et al., 2005).
Untreated cortical neurons in culture experience significant
levels of spontaneous synaptic (but not extrasynaptic) NMDAR
activity (Papadia et al., 2008). Although this activity ismoremod-
est than that experienced in response to BiC/4-AP treatment, its
pro-survival effect can be studied by blocking it with MK-801.
Blockade of spontaneous NMDAR activity with MK-801 exacer-
bated death in these models of apoptosis (Fig. 1A). Of particular
note, the level of neuronal apoptosis in untreated neurons subject
to 72 h of trophic deprivation was relatively low but was also
dramatically increased byMK-801 treatment (Fig. 1A). Thus, the
level of synaptic NMDAR activity [namely, comparing none
(MK-801) vs low-level spontaneous activity (untreated control)
vs AP burst-induced activity (BiC/4-AP)] correlated well with
resistance to a variety of apoptotic insults. Consistent with its
protective effect, BiC/4-AP treatment blocked caspase-3/7 acti-
vation induced by staurosporine treatment (Fig. 1B), as we re-
cently found in the case of peroxide treatment (Papadia et al.,
2008). The protective effect of BiC/4-AP treatment was reversed by
MK-801 (Fig. 1A). Furthermore, blockadeof spontaneousNMDAR
activity by MK-801 caused an increase in staurosporine-induced
caspase-3/7 activity and strongly induced caspase-3/7 activity in
trophically deprived neurons (Fig. 1B). Thus, synapticNMDAR ac-
tivity suppresses the activation of executioner caspases following an
apoptotic insult.
Release of mitochondrial cytochrome c into the cytoplasm is
an important apoptotic control point (Meier andVousden, 2007)
that leads to the formation of the Apaf-1-containing apoptosome
and recruitment/activation of procaspase-9, an initiator caspase.
Cytochrome c release is characterized by loss of punctate mito-
chondrial localization and appearance of diffuse cellular staining,
followed quickly by complete loss of staining as the cell undergoes
apoptosis (Wyttenbach and Tolkovsky, 2006). We found that
exposure of neurons to staurosporine promoted cytochrome c
release frommitochondria: cytochrome c staining was either ab-
sent in apoptotic cells or diffuse throughout the cell (Fig. 1C,D).
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Blockade of spontaneous NMDAR activity with MK-801 re-
sulted in an increase in the proportion of staurosporine-treated
neurons exhibiting cytochrome c loss (Fig. 1C,D). With BiC/4-
AP-stimulated neurons exposed to staurosporine, a far smaller
percentage of neurons exhibited cytochrome c release than with
control neurons [15 2% compared to 40 3%, p	 0.05 (n
4)] (Fig. 1D), clearly indicative of protective mechanisms up-
stream of release. However, considering only the cytochrome
c-negative cells in isolation, a larger proportion of these had
normal, nonpyknotic nuclear morphology in the BiC/4-AP-
stimulated group than in the control group [18 2% compared
to 5 2%, p	 0.05 (n 4)] (Fig. 1C, white arrows), indicative of
some inhibition of apoptotic processes downstream of cyto-
chrome c release. Mechanisms downstream of cytochrome c re-
lease could involve regulation of apoptosome components,
Apaf-1 and caspase-9, or other events downstream of caspase-9
activation, as illustrated by the fact that the pan-caspase inhibitor
QVD-Oph also inhibits nuclear pyknosis downstream of cyto-
chrome c release (supplemental Fig. S2a, available at www.
jneurosci.org as supplemental material). Regulation of pro- and
anti-apoptotic members of the Bcl2 family offer a potential
mechanism by which synaptic activity could prevent cytochrome
c release following an insult. Qualitatively similar results regard-
ing cytochrome c were obtained using hydrogen peroxide as the
apoptosis-inducing agent (supplemental Fig. S2b, available at
www.jneurosci.org as supplemental material). In this instance
activity-dependent enhancement of intrinsic antioxidant de-
fenses (Papadia et al., 2008) may also contribute to prevention of
cytochrome c release, in addition to the general anti-apoptotic
mechanisms under investigation here.
The release of Smac/Diablo from mi-
tochondria can cooperate with cyto-
chrome c release in promoting apoptosis
by suppressing the inhibitors of apoptosis
(IAPs). However, in our hands, mito-
chondrial localization of Smac/Diablo
was not perturbed until after cytochrome
c release, and in the largemajority of cases,
after nuclear pyknosis (G. E. Hardingham,
unpublished observations), suggesting that
Smac/Diablo release is not a key apoptotic




Puma is a pro-death BH3-only domain
member of the Bcl2 superfamily, which is
an important regulator of neuronal apo-
ptosis in response to a variety of injuries,
including oxidative stress, staurosporine,
and trophic deprivation (Wyttenbach
and Tolkovsky, 2006; Kieran et al., 2007;
Steckley et al., 2007). We found that induc-
ing AP bursting with BiC/4-AP treatment
resulted in the downregulation of Puma
mRNA and protein expression, an effect re-
versed by coapplication of MK-801 (Fig.
2A,B). Moreover, BiC/4-AP treatment re-
duced Puma upregulation by staurosporine
in anNMDAR-dependentmanner (supple-
mental Fig. S3, available at www.jneurosci.
org as supplemental material).
In addition to the Puma-suppressing effects of enhancing syn-
aptic NMDAR activity by BiC/4-AP stimulation, we investigated
whether spontaneous synaptic NMDAR activity in untreated
control cultures has a Puma-suppressing effect. We found that
blockade of spontaneous synaptic NMDAR activity caused an
upregulation of Puma expression. The most likely mechanism of
activity-dependent suppression of Puma expression is transcrip-
tional, although other potential mechanisms exist, such as regu-
lation of mRNA stability. Consistent with a direct effect on the
transcriptional activity of the Puma promoter, activity of a
luciferase-based reporter of the Puma promoter (Puma-Luc (Wu
et al., 2005)), was suppressed by BiC/4-AP stimulation (Fig. 2C).
Suppression of physiological NMDAR activity promotes neuro-
nal loss and exacerbates neurodegeneration in vivo (Ikonomidou et
al., 1999, 2000; Adams et al., 2004; Tashiro et al., 2006). We
therefore tested whether physiological NMDAR activity also
suppresses Puma expression in vivo. P6 mice were injected with
MK-801, whichwe recently showed induces widespreadTUNEL-
positive cell death in the cortex 24 h after injection (Papadia et al.,
2008) as was reported for rat brains (Ikonomidou et al., 1999).
Analysis of Puma expression in advance of this time (at 12 h
after injection) revealed significant upregulation by MK-801
administration (2.2 0.2-fold, p	 0.05), indicative of a sup-
pressive effect of physiological NMDAR activity on Puma ex-
pression in vivo.
While transsynaptic activation of synaptic NMDARs is anti-
apoptotic, chronic activation of all (synaptic and extrasynap-
tic) NMDARs by bath application of glutamate/NMDA is not
(Hardingham et al., 2002). Moreover, synaptic and bath activa-
tion of NMDARs promote very different transcriptional re-
Figure2. Activity-dependent suppression of the proapoptotic genePumaprotects neurons.A, Activity-dependent suppression
of the proapoptotic gene Puma. QRT-PCR analysis of Puma expression in cortical neurons treated with the indicated drugs.
B, Western blot illustrating regulation of Puma expression at the protein level. C, The Puma promoter is sufficient to confer
activity-dependent suppression on a reporter gene. Neurons were transfected with a Puma-luciferase reporter, plus a TK-Renilla
control vector. At 24 h after transfection, neurons were stimulated for the indicated times, and firefly luciferase reporter
activity was measured, normalized to the Renilla control. *p 	 0.05, Student two-tailed t test (n  4). D, E, Puma
expression is sufficient to induce apoptosis in cortical neurons. Neurons were transfected with the indicated vectors, plus a
vector encoding eGFP as a transfection marker. Transfected neurons were identified after 10 h, and their fate was moni-
tored at 20 and 30 h. *p	 0.05 (n 3).
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sponses (Zhang et al., 2007). We therefore tested whether
transsynaptic activation of synaptic NMDARs is critical for
NMDAR-dependent suppression of Puma expression. We bath
applied a range of glutamate doses to determinewhether any dose
is able to result in the transcriptional repression of the apoptotic
genes described in this study. Glutamate was applied in the pres-
ence of TTX to prevent preferential activation of synaptic
NMDARs (Soriano et al., 2006). We found that no dose of gluta-
mate resulted in significant suppression of Puma expression
(supplemental Fig. S4, available at www.jneurosci.org as supple-
mental material), suggesting that NMDAR-dependent suppres-
sion of Puma is restricted to the transsynaptic activation of
synaptic NMDARs, and is not a preconditioning-type effect in
response to subtoxic glutamate exposure.
Studies have shown that expression of Puma is sufficient to
induce apoptosis in immature cortical neurons [E15.5 cultured
for 3–4 d in vitro (Steckley et al., 2007; Uo et al., 2007)] and in
DIV6 postnatal cortical neurons (Wong et al., 2005). To confirm
this in our system, neurons were transfected with a vector encod-
ing wild-type Puma driven by a constitutively active promoter,
plus a vector encoding eGFP to identify transfected cells. At 10 h
after transfection, GFP-positive neurons were observed. By ob-
serving these cells at 20 and then 30 h after transfection, we found
that they die rapidly even when held in trophic medium (Fig.
2D,E). In contrast, when the neurons were transfected with ei-
ther a control (-globin) vector or a vector encoding a mutant
form of Puma lacking its pro-death BH3 domain, Puma-
BH3
(Yu et al., 2001; Wong et al., 2005), these cells did not die (Fig.
2D,E). Furthermore, we observed more control- and Puma-

BH3 transfected cells per field at 10 h than Puma-expressing
cells, suggesting that many Puma-expressing cells were already
dead even at 10 h after transfection. The fact that Puma is suffi-
cient to trigger apoptosis indicates that its suppression may have
a profound protective effect.
We investigated the importance of synaptic NMDAR activity-
dependentPuma suppression inactivity-dependentneuroprotection
by studying cortical neurons cultured from Puma-deficient
mice. We found that levels of apoptosis were significantly re-
duced in Puma-deficient neurons subjected to staurosporine
treatment (Fig. 3A). Not only did Puma-deficient neurons
treated with staurosporine show normal nuclear morphology,
but the neurons appeared healthy under phase contrast (Fig. 3B)
and could all fire action potentials when patched and injected
with current (supplemental Fig. S5, available at www.jneurosci.
org as supplemental material). Moreover, mitochondrial cyto-
chrome c localization was retained in Puma-deficient neurons
treated with staurosporine, as would be expected given its posi-
tion in the apoptosis pathway (supplemental Fig. S6, available at
www.jneurosci.org as supplemental material). Also of note, ex-
pression of Puma (but not Puma-
BH3 in Puma-deficient neu-
rons effectively triggered apoptosis (supplemental Fig. S7,
available at www.jneurosci.org as supplemental material), indi-
cating that developmental loss of Pumahas not caused disruption
to the rest of the apoptosis machinery.
We also observed thatMK-801 did not exacerbate staurosporine-
induced death as it does in wild-type cells (Fig. 3A). Puma defi-
ciency also blocked apoptosis induced by prolonged exposure
of neurons to MK-801 in trophically deprived medium (Fig.
3C,D). Thus, Puma deficiency abrogates the need for neuro-
protective synaptic NMDAR activity, consistent with the hy-
pothesis that Puma suppression is a key protective mechanism
induced by synaptic NMDAR activity. To offset the possibility
that Puma/ neurons had a developmental deficiency in their
apoptosis pathway, we also studied the effect of siRNA-directed
against Puma in wild-type neurons, which protected neurons
againstMK-801 and staurosporine-induced cell death, compared
to a control siRNA (supplemental Fig. S8, available at www.
jneurosci.org as supplemental material). This effect could be
overcome by overexpressing human Puma, which contains sev-
eral mismatches at the targeted regions (data not shown). Thus,
the Puma siRNA data are consistent with the data obtained from
Puma knock-out neurons.
Finally, we investigated neuronal death in response to hydro-
gen peroxide. In this model of apoptosis, we found that BiC/4-
AP-induced synaptic activity still exerted some protection in
Puma-deficient neurons, despite dramatically lower levels of
death overall (supplemental Fig. S9, available at www.jneurosci.
org as supplemental material). This is consistent with neuropro-
tection against oxidative stress-induced apoptosis involving
more than just Puma downregulation. Indeed, we know this to be
the case: intrinsic antioxidant defenses are enhanced by synaptic
NMDAR activity (Papadia et al., 2008) and are likely to act in
concert with anti-apoptotic Puma suppression.
Synaptic activity can promote survival downstream of
Puma expression
We observed that AP-bursting appears to block chromatin frag-
mentation in a few cases without preventing cytochrome c release
(Fig. 1D). We therefore wanted to determine whether AP burst-
ing could inhibit apoptotic processes downstream of Puma
upregulation. To do this, we transfected neurons with a Puma-
encoding vector, and determined the effect of AP bursting on the
number of Puma-expressing cells visible at 10 h after transfec-
tion. The cultureswere treatedwithBiC/4-APbefore, during, and
after transfection. We observed that AP bursting induced a spe-
cific increase in eGFP/Puma-expressing cells. We confirmed that
the eGFP-positive neuronswere immunopositive for Puma (sup-
plemental Fig. S10, available at www.jneurosci.org as supplemen-
tal material). We did not observe any increase in the numbers of
globin- or Puma-
BH3-expressing neurons as expected, since
these cells were not dying. Nevertheless, to control for any subtle
nonspecific effect of AP bursting, we expressed the effect of BiC/
4-AP treatment on the number of Puma-expressing cells relative
to its effect on both globin- andPuma-
BH3-expressing neurons
(Fig. 3E). The effect of BiC/4-AP-induced AP bursting was to
specifically increase the number of Puma-expressing neurons
(both relative to control and Puma-
BH3-expressing neurons),
indicating that burst activity is inhibiting Puma-induced apoptosis.
To obtain a better idea of the extent to which AP burst activity
inhibits Puma-induced apoptosis, we compared its effect to that
of QVD-Oph treatment, which inhibits caspase-dependent apo-
ptosis and so should also inhibit the death of Puma-expressing
neurons in the short term. As was observed with BiC/4-AP
treatment, QVD-Oph resulted in a specific increase in Puma-
expressing neurons observed relative to its effect on both
globin- and Puma-
BH3-expressing neurons (Fig. 3E). The
effect of BiC/4-AP treatment was 60% of that of the pan-
caspase inhibitor, indicative of substantial inhibition of Puma-
induced apoptosis.
We next investigated whether the inhibition/delay of Puma-
induced apoptosis by synaptic activity is exerted upstream or
downstream of cytochrome c release. We found that 67 7% of
Puma-overexpressing, BiC/4-AP-stimulated neurons exhibited
cytochrome c loss (Fig. 3F,G). By comparison, only 5  3% of
neurons expressing the inactive mutant Puma-
BH3 exhibited
apparent cytochrome c loss. We compared these figures to those
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obtained in neurons treated with the
pan-caspase inhibitor QVD-Oph, since
protection afforded by this inhibitor
would be expected to be exerted down-
stream of cytochrome c release, finding
that 77  8% of Puma-overexpressing,
QVD-treated neurons exhibited cyto-
chrome c loss, a similar figure to that ob-
tained with BiC/4-AP-treated neurons
(Fig. 3F,G). We conclude from this that
synaptic activity does indeed inhibit Puma-
induced neuronal death by acting down-
stream of cytochrome c release, suggesting
the existenceof an additional anti-apoptotic
pathway.
Synaptic activity suppresses expression
of Apaf-1 and procaspase-9
Cytochrome c release into the cytoplasm
and its binding to Apaf-1 triggers Apaf-1
multimerization (forming the apopto-
some). The apoptosome then induces ac-
tivation of procaspase-9, the initiator
caspase (Meier and Vousden, 2007). Syn-
aptic NMDAR activity reduced levels of
caspase-9 activity following trophic depri-
vation and 100 nM staurosporine (Fig.
4A), similar to its effect on caspase-9 ac-
tivation following peroxide treatment
(Papadia et al., 2008). While this is un-
doubtedly due largely to prevention of cy-
tochrome c release, we also examined
whether expression of Apaf-1 or caspase-9
are altered by synaptic activity, since this
could represent a control point down-
stream of cytochrome c release. We
found that expression of genes encoding
procaspase-9 (Casp9) and Apaf-1 (Apaf1)
were strongly suppressed by AP bursting
(Fig. 4B). Activity of luciferase-based re-
porters of both the Casp9 and Apaf1 pro-
moters (Moroni et al., 2001; Tsujimoto et
al., 2005) were also suppressed by AP
bursting (Fig. 4C), strongly suggesting a
direct effect on the transcription of these
genes (as opposed to any posttranscrip-
tional effects). The suppression of Apaf-1
and procaspase-9 expression by firing ac-
tivity raises the possibility that a stronger
or more widespread mitochondrial dys-
function may be required to trigger apo-
ptosis in electrically active neurons. In
neuronal cells, developmentally regulated
lowering of Apaf-1 expression is known to
increase resistance to release of cyto-
chrome c (Potts et al., 2003; Wright et al.,
2004). We therefore investigated whether
lowered levels of procaspase-9 expression
can also impede apoptosis in neurons.We
hypothesized that during progressive
neuronal degeneration, such as that in-
duced by prolonged trophic deprivation,
the level of procaspase-9 expression may
Figure 3. Synaptic activity can suppress the proapoptotic effect of Puma upregulation. A, B, The neuroprotective effect of
synaptic activity against staurosporine-induced apoptosis is occluded by Puma deficiency. Both wild-type and Puma-deficient
neurons were stimulated as indicated for 16 h before the addition of staurosporine (100 nM) where indicated, for a further 24 h.
After 24 h cell death was assessed. *p	 0.05 (n 4) indicates stimulus-dependent differences (n 4). #p	 0.05 indicates
differences due to genotype (i.e., compared to/ neurons treated in the same way); “ns” indicates no significant statistical
difference.B, Examplephase-contrastpicturesalongside thesamefieldof cells after fixationandDAPI stainingofnuclei. Scalebar,50m.
C,D, The neuroprotective effect of synaptic activity against trophic deprivation-induced apoptosis is occluded by Puma deficiency. Wild-
typeandPuma-deficientneuronswere treatedas indicated for72h in trophicallydeprivedmedium,afterwhichcellswere fixedand levels
of cell death assessed. *p	 0.05 (n 4). *p	 0.05 (n 4) indicates stimulus-dependent differences (n 4). #p	 0.05 indicates
differencesdue togenotype (i.e., compared to/neurons treated in the sameway); “ns” indicatesno significant statistical difference.
D, Examplephase-contrastpicturesalongside thesamefieldof cellsafter fixationandDAPI stainingofnuclei. Scalebar,50m.E, Synaptic
activity can suppress the proapoptotic effect of Puma upregulation. Neurons were treated where indicated with BiC/4-AP starting 24 h
beforebeing transfectedwithpeGFPplus vectors encodingeitherPuma,-globin, orPuma-
BH3.Whereused,QVD-Ophwasapplied to
neurons1hbefore transfection.Foreachexpressionvector,andforeachtreatment, thenumberofviableneuronsper fieldwasanalyzedat
10 h after transfection. The effect of BiC/4-AP-induced AP burst activity, or the effect of QVD-Oph, on the number of Puma-expressing
neurons seen isexpressed relative to theeffectof these treatmentson thenumberofneuronsexpressing the twocontrol vectors (globin
and Puma-
BH3). *p	 0.05 (n 6). F,G, Suppression of Puma-induced apoptosis by synaptic activity or caspase inhibition is down-
streamofcytochromec release.NeuronsareshownexpressingeGFPpluseithercontrolvector (-globin),PumaorPuma-
BH3.To inhibit
Puma-induced apoptosis neurons were either pretreated with BiC/4-AP or QVD-Oph, as described in the text. At 10 h after transfection
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influence the rate of apoptosis. To test whether levels of
procaspase-9 can influence the rate of death, we overexpressed
procaspase-9 andmonitored the rate of neuronal death during
trophic deprivation. We found that in AP bursting neurons,
the rate of apoptosis was significantly increased by overexpress-
ingCasp9 (Fig. 4E,F), an effect reversed byMK-801 (supplemen-
tal Fig. S12, available at www.jneurosci.org as supplemental
material). However, procaspase-9 overexpression did not alter the
rate of apoptosis in unstimulated neurons (Fig. 4D,F). Together
these experiments suggest that the level of procaspase-9 expres-
sion is not a limiting factor in apoptosis in electrically quiet neu-
rons, but that in firing neurons, where procaspase-9 levels are
suppressed (as indeed is Apaf-1), it may become limiting.
Synaptic activity does not exert significant protection
downstream of caspase-9 activation
We next wanted to determine whether synaptic activity could
exert any anti-apoptotic effects downstream of caspase-9 activa-
tion. Several potential control points exist, such as changes in
expression of IAPs (Potts et al., 2003) or of executioner caspases.
QRT-PCR analysis revealed that AP bursting caused the transcrip-
tional suppression of the gene encoding procaspase-3 (Casp3), one
of the executor caspases downstream of caspase-9 activation (Fig.
5A). This raised the possibility that apoptosis may be inhibited or
slowed downstream of caspase-9 activation.
To investigate protection downstreamof caspase-9 activation,
we used an inducible form of caspase-9 [icasp9 (No¨r et al., 2002)]
that comprises the procaspase-9 zymogen fused to a modified
version of FK-506 binding protein. This undergoes dimerization
when cells are treated with a cell-permeable dimerizer: a bivalent,
modified version of FK-506, AP20187 (Ariad). Upon dimeriza-
tion, icasp9 activates its dimer partner, releasing active caspase-9.
In icasp9-expressing cortical neurons, addition of AP20187 re-
sulted in cell death that was blocked by QVD-Oph (Fig. 5B).
Neither dimerizer alone nor icasp9 expression alone affected vi-
ability (Fig. 5B). AP20187 killed icasp9-expressing neurons in a
dose-dependent manner at very low concentrations (Fig. 5C).
Importantly, BiC/4-AP-induced synaptic activity did not reduce
cell death caused by artificial caspase-9 activation, even at thresh-
old concentrations of AP20187 (Fig. 5C). This experiment
indicates that protective pathways downstream of caspase-9 ac-
Figure 4. Synaptic activity suppresses the expression of Apaf-1 and procaspase-9. A, Synaptic NMDAR activity inhibits activation of caspase-9 in response to an apoptotic insult. Neurons were
treated with the indicated compounds as described in Figure 1A. Caspase-9 activity was measured after 48 h trophic deprivation, or 16 h staurosporine treatment. *p	 0.05 (n 4). B, Synaptic
NMDAR activity suppresses expression of apoptosome components. QRT-PCR analysis of Apaf1 and Casp9 expression in neurons. *p	 0.05 (n 4). Inset shows exampleWestern blot illustrating
BiC/4-AP-induced suppression of protein expression. C, Promoter regions ofApaf1 and Casp9 confer activity-dependent suppression on a luciferase reporter gene. Neuronswere transfectedwith the
indicated reporters, plus a TK-Renilla control vector. At 24 h after transfection, neurons were stimulated for the indicated times and firefly luciferase reporter activity was measured, normalized to
the Renilla control. *p	 0.05 (n 3). D, E, Overexpression of procaspase-9 accelerates apoptosis in AP-bursting but not control neurons. Neurons expressing eGFP plus either a control vector
(globin) or a vector encodingprocaspase-9wereplaced in trophically deprivedmediumandeither left unstimulated (D) or treatedwithBiC/4-AP to induceAPbursting (E). Picturesofneuronswere
taken at 24 h and then their viability was monitored at 24 h intervals. *p	 0.05 (n 5). F, Example pictures relating to D and E.
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tivation are not a significant aspect of the anti-apoptotic effects of
synaptic activity.
Activity-dependent suppression of Puma, Apaf1, and Casp9
transcription in cortical neurons is not via p53 inhibition
It was recently shown that synaptic activity induces suppression
of the proapoptotic transcription factor p53 in hippocampal neu-
rons, and that knockdown of p53 is sufficient to protect neurons
against apoptotic insults (Lau and Bading, 2009). We therefore
investigated whether suppression of p53 is the mechanism by
which synaptic activity suppresses expression of Puma, Apaf1,
and Casp9 in cortical neurons, especially since p53 is implicated
in the regulation of Puma and Apaf1 (Moroni et al., 2001; Yu et
al., 2001). BiC/4-AP-induced synaptic activity suppressed p53
expression by 30% in cortical neurons, to levels that remain
higher than in neurons cultured from p53 heterozygous /
mice (Fig. 6A). Puma levels were not altered in p53/ neurons
(Fig. 6B), despite the50% reduction in p53 mRNA levels (Fig.
6A), indicating that the 30% suppression of p53 expression by
synaptic activity would not be sufficient to alter Puma levels.
Analysis of p53 / neurons revealed that levels of Puma were
33% lower than in p53 / neurons, consistent with a role for
p53 in Puma transcription (Fig. 6B). However, levels of Puma in
unstimulatedp53/neuronswere still significantlyhigher than in
BiC/4-AP-stimulated wild-type neurons (Fig. 6B). Furthermore,
BiC/4-AP stimulation still suppressed Puma expression in p53/
neurons (Fig. 6B). The percentage reduction ofPuma expression by
BiC/4-AP stimulation in p53/ and p53/ neurons was un-
changed (59 6% and 54 6%, respectively). In addition, MK-
801 treatment resulted in a significant increase in Puma
expression in p53/ neurons (Fig. 6B). These data are consis-
tent with p53 suppression not having a significant role in medi-
ating the synaptic NMDAR-dependent Puma suppression (Lau
and Bading, 2009). Moreover, p53 suppression is not involved in
Apaf1 or Casp9 regulation since p53 deficiency had no effect on
basal or activity-suppressed levels of Apaf1 or Casp9 (Fig. 6C).
Acute knockdownof p53 has been shown to reduceApaf1 expres-
sion in hippocampal neurons (Lau and Bading, 2009), so we
lookedmore carefully at this promoter.We analyzed the activity-
dependent suppression of the Apaf1 promoter both with and
without its two p53 binding sites, using luciferase reporters pre-
viously generated (Moroni et al., 2001). We observed a similar
Figure 5. Synaptic activity does not exert protection downstream of caspase-9 activation.A, QRT-PCR analysis of Casp3 expression in neurons stimulated as indicated. *p	 0.05 (n 3).B, The
inducible caspase-9 system enables neurons to be killed by treatmentwith the dimerizer drug AP20187. Neuronswere transfectedwith peGFP plus either control or icaspase-9 encoding vectors. At
24 h after transfection pictures of neurons were taken before the treatment, where indicated, with AP20187 (100 pM), to cause dimerization/activation of icaspase-9. Cell death was assessed after
a further 24 h. Where used, QVD-Oph was applied 1 h before AP20187. *p	 0.05 (n 4). Inset shows example pictures. C, Synaptic activity cannot protect against icaspase-9-induced apoptosis.
Neurons were transfected as in B and immediately left either unstimulated or treated with BiC/4-AP to induce burst activity. At 24 h after transfection pictures of cells were taken before treatment
with the indicated concentrations of AP20187. Cell death was assessed after a further 24 h (n 4).
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amount of activity-dependent suppres-
sion of the Apaf1 promoter in the pres-
ence or absence of its p53 sites, further
suggesting that activity-dependent reduc-
tion of Apaf1 is not mediated by p53 in
cortical neurons (supplemental Fig. S13,
available at www.jneurosci.org as supple-
mental material).
We next analyzed the vulnerability of
p53/and/neuronstostaurosporine-
induced apoptosis. We found that stauro-
sporine-induced apoptosis was slightly
lower in p53/ neurons, but unchanged
in p53/ neurons (Fig. 6D). BiC/4-AP-
induced synaptic activity still resulted in
strong protection in p53 / and /
neurons, and MK-801 still increased levels
of apoptosis (Fig. 6D). In our trophic depri-
vation model, the reduction in levels of
death in p53/ neurons was not statisti-
cally significant. Moreover, BiC/4-AP-
induced synaptic activity still resulted in
strong protection in p53 / and /
neurons, and MK-801 still increased levels
of apoptosis (Fig. 6E).We conclude that the
activity-dependent protective pathways de-
scribed here in cortical neurons are not
dependent onp53 suppression.Anyprotec-
tive effect arising from p53 suppression will
cooperate with the mechanisms described
here to strongly suppress apoptosis.
Discussion
We have shown that key components of
the neuronal intrinsic apoptosis pathway
are subject to activity-dependent tran-
scriptional shut-off, mediated largely by
synaptic NMDAR activity. The result of
these gene expression changes is to restrict
the capacity of neurons to undergo apo-
ptosis in response to a diverse array of
stimuli.
Synaptic NMDAR activity upregulates
protective genes and downregulates
pro-death genes
In contrast to the adverse effects of exces-
sive NMDAR activity, physiological levels
of synaptic NMDAR activity are essential
for neuronal survival, since activity block-
ade was shown to have deleterious effects. Blockade of NMDAR
activity in vivo caused a decrease in the number of healthy cells,
increased density of pyknotic cells, and severe deterioration of the
dentate gyrusmorphology in first week postnatal rat pups (Gould
et al., 1994). Elimination of NMDA receptor activity in vivo
causes widespread apoptosis and enhances trauma-induced in-
jury in developing neurons (Gould et al., 1994; Ikonomidou et al.,
1999; Pohl et al., 1999; Monti and Contestabile, 2000; Adams et
al., 2004; Papadia et al., 2008). In the adult CNS, NMDAR block-
ade exacerbates neuronal loss when applied after traumatic brain
injury and during ongoing neurodegeneration (Ikonomidou et
al., 2000), and prevents the survival of newborn neurons in the
adult dentate gyrus (Tashiro et al., 2006). NMDAR signaling to
survival has been recapitulated in vitro in neuronal cultures (Har-
dingham, 2006; Hetman and Kharebava, 2006), allowing the un-
derlying signaling events to be investigated. While pro-survival
signaling from the NMDA receptor can involve posttranslational
modifications of existing proteins, it is clear that changes in gene
expression play a major role.
The negative coupling of several key proapoptotic genes to
synapticNMDARactivity,Puma,Apaf1,Casp9,Casp3, andTrp53
[this study and Lau and Bading (2009)], helps to explain how
synaptic NMDAR activity can prevent apoptosis largely indepen-
dent of the type of insult used. Unpublished microarray data
from our laboratory indicate that the influence of synaptic
NMDAR activity on core components of the intrinsic apoptosis
pathway is restricted to the genes studied in this manuscript. Of
Figure 6. Neuroprotectiondue toactivity-dependent suppressionof Puma,Apaf-1, andProcaspase-9expression is not viap53 inhibi-
tion.A, QRT-PCRanalysis ofp53 expression inp53/ and/neurons thatwere stimulated as indicated for 4h. *p	0.05 (n6
/,n4/).B,QRT-PCRanalysisofPumaexpressioninp53/,/,and/neuronsthatwerestimulatedasindicated.
MK-801 treatment was for 24 h. BiC/4-AP treatment was for 4 h. *p	 0.05 (n 6/, n 4/, n 4/) indicates
stimulus-dependentdifferences (n4). #p	0.05 indicatesdifferencesduetogenotype(i.e., comparedto/neurons treated in the
sameway). @p	0.05comparedto levelofneuronaldeath inBiC/4-AP-stimulated,p53/neurons.C,QRT-PCRanalysisofApaf1and
Casp9 expression in p53/,/, and/ neurons stimulated where indicated with BiC/4-AP for 4 h. #p	 0.05 compared to
control of that particular genotype (n 6/, n 4/, n 4/).D, The neuroprotective effect of synaptic activity against
staurosporine-inducedapoptosis isnotoccludedbyp53deficiency.p53/,/,and/neuronswerestimulatedasindicatedfor
16hbefore theadditionof staurosporine (100nM)where indicated, for a further 24h.After 24h, cell deathwasassessed. *p	0.05 (n
6/,n4/,n4/) indicates stimulus-dependentdifferences (n4). #p	0.05 indicatesdifferencesduetogenotype
(i.e., compared to/ neurons treated in the sameway). E, The neuroprotective effect of synaptic activity against trophic deprivation-
induced apoptosis is not occluded by p53 deficiency. p53/,/, and/ neurons were stimulated as indicated for 72 h in
trophically deprived medium, after which cell death was assessed. *p	 0.05 (n 6/, n 4/, n 4/) indicates
stimulus-dependentdifferences (n4). #p	0.05 indicatesdifferencesduetogenotype(i.e., comparedto/neurons treated in the
sameway). There are no such differences.
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the caspases, onlyCasp9 andCasp3 are altered by BiC/4-AP treat-
ment (and in a NMDAR-dependent manner). Furthermore, we
find little evidence that anti-apoptotic members of the Bcl2 fam-
ily are globally upregulated: within this group, no member is
induced (using 1.5-fold as the threshold), nor are any IAP genes
upregulated. Of all the proapoptotic members of the Bcl2 family
(including the Bax subfamily), Puma is the only gene suppressed
by BiC/4-AP treatment. However, we observed an upregulation
of Bcl2l11 (Bim) andHrk expression by MK-801 treatment, con-
firmed by qPCR (data not shown). Thus, while regulation of Bim
or Hrk is not associated with neuroprotection evoked by strong
synaptic NMDAR activity evoked by BiC/4-AP, induction of
these genesmay contribute in part to apoptosis induced by block-
ing all NMDAR activity by MK-801. However, given that MK-
801-induced death is abolished in Puma-deficient neurons (Fig.
3C), this shows that Bim and Hrk induction are not sufficient to
trigger apoptosis in the absence of Puma. This is consistent with
studies that suggest a stronger role for Puma in neuronal apopto-
sis than Hrk or Bim, potentially due to it being a stronger direct
activator of Bax (Steckley et al., 2007; Ghosh et al., 2009).
The pro-survival effects of shutting off key components of the
intrinsic apoptotic machinery is accompanied by further protec-
tion mediated by the nuclear Ca2-dependent upregulation of
pro-survival gene expression, mediated by CREB and potentially
other factors (Hardingham et al., 2001; Papadia et al., 2005;
Zhang et al., 2009a). Such genes includeBdnf (Hardingham et al.,
2002; Soriano et al., 2006), Btg2, a potentially anti-apoptotic
CREB target gene, and Bcl6, a transcriptional repressor impli-
cated in suppression of p53 (Zhang et al., 2007) as well as several
other nuclear Ca2-regulated neuroprotective genes very re-
cently identified (Zhang et al., 2009a). The anti-apoptotic effects
of the above-mentioned changes in gene expression are aug-
mented by others in the context of promoting resistance to one
apoptotic insult of particular relevance to neurodegeneration:
oxidative stress. Synaptic NMDAR activity induces strong up-
regulation of intrinsic antioxidant defenses involving increased
capacity of both the thioredoxin/peroxiredoxin system (Papadia
et al., 2008) and the glutathione system (G. E. Hardingham, un-
published observations). As well as detoxifying harmful radicals
and ROS, the reducing capacity of these systems may directly
influence the intrinsic apoptosis cascade, since reduction of cyto-
chrome c (to the Fe2 form) renders it unable to trigger apopto-
some formation and caspase activation (Brown and Borutaite,
2008).
The changes in antioxidant defenses triggered by synaptic ac-
tivity are mediated by a coordinated program of gene expression.
For example, synaptic activity induces expression of sulfiredoxin,
the enzyme responsible for reduction of hyperoxidized peroxire-
doxins, as well as suppressing expression of the thioredoxin in-
hibitor Txnip (Papadia et al., 2008). The latter represents the first
example of a pro-death gene whose expression is suppressed by
synaptic activity.We found Txnip to be subject to transcriptional
regulation by the FOXO (forkhead box O) subfamily of forkhead
transcription factors, inactivated when induction of the PI3K
(phosphoinositide-3-kinase)–Akt kinase cascade results in ex-
port of FOXOs from the nucleus to the cytoplasm.
Despite the phosphoinositide-3-kinase (PI3K)-dependent sup-
pression of FOXO activity and expression by synaptic activity (Al-
Mubarak et al., 2009), and reported involvement of FOXOs in the
expression of Puma, PI3K inhibition did not interfere with suppres-
sion of Puma, nor indeedApaf1,Casp9, orCasp3 (data not shown),
raising the question as to themechanism involved. Puma andApaf1
are also reported p53 targets, but suppression of these genes was
observed in p53-deficient neurons, ruling out p53 inhibition as a
dominant mechanism in cortical neurons (Fig. 6). Of note, Apaf-1
expression is sensitive to reduction in p53 levels in hippocampal
neurons (Lau and Bading, 2009), suggesting that basal p53 activity
may be higher in hippocampal neurons than cortical neurons.
We considered whether enhanced histone acetylation may
underlie suppression of these proapoptotic genes, since activity-
mediated changes in promoter acetylation status do occur (Soriano
et al., 2009). We found that inhibition of Class I and II histone
deacetylases by treatment with trichostatin A (TSA) did not ele-
vate basal expression of Puma or Casp9, nor did it block their
activity-dependent suppression (data not shown). In the case of
Apaf1, TSA treatment resulted in upregulation of its expression
(data not shown), as has been shown in sympathetic neurons
(Wright et al., 2007). However, induction of synaptic activity still
resulted in its transcriptional suppression (data not shown).
Thus, changes in histone acetylation are unlikely to be involved in
activity-dependent suppression of these proapoptotic genes.
Apoptotic biochemical cascades in neurodegenerative disease
Although the issue remains controversial, there is growing evi-
dence that the death of neurons in many neurodegenerative dis-
eases can occur by apoptosis or related mechanisms that involve
apoptotic biochemical cascades (Mattson, 2006; Ribe et al., 2008;
Rohn and Head, 2009). Increased levels of activated caspase-9
have been observed in Alzheimer’s disease (AD, hippocampus),
Huntington’s disease (HD, striatum), Parkinson’s disease (PD,
substantia nigra), and amyotrophic lateral sclerosis (ALS, spinal
cord) (Kiechle et al., 2002; Inoue et al., 2003; Tatton et al., 2003;
Ribe et al., 2008; Rohn andHead, 2009), implicating the intrinsic
apoptosis pathway in disease progression. Furthermore, apopto-
sis and caspase activation are implicated in multiple in vitro and
animalmodels of neurodegeneration (Ferraro et al., 2003;Mattson,
2006;Ribeetal., 2008). Inhibitionofcaspaseshasbeenreported tobe
protective inmodels of ALS, HD, and PD (Friedlander, 2003; Rohn
andHead, 2009).
In AD, there is good evidence that caspases have a proximal
role in disease progression and not just in terminal neurodegen-
eration (Rohn and Head, 2009). Increased expression of
procaspase-9 has been observed in AD brains, as well as other
caspases (Cotman and Anderson, 1995) and activation of
caspases is also observed even in subjects with mild AD (Gastard
et al., 2003; Rohn and Head, 2009). Amyloid  ()-induced
oxidative stress triggers caspase activation through the intrinsic
mitochondrial pathway. Executioner caspases, particularly
caspase-3, then cleave APP, which may facilitate the production
of A (Gervais et al., 1999), potentially resulting in a feedforward
cycle of A production and caspase-3 activation. Tau is also a
substrate for Caspase-3, and cleavage of tau may promote aggre-
gation and paired helical filament formation (Gamblin et al.,
2003; Rohn and Head, 2009). Caspase activation is also impli-
cated in localized neurite and nerve terminal degeneration
(Marx, 2001), which may occur well in advance of any cell death.
Recently the benefits of inhibiting the intrinsic apoptotic bio-
chemical cascade were demonstrated in the triple transgenic AD
mouse model (Oddo et al., 2003; Rohn et al., 2008). Overexpres-
sion of the antiapoptotic Bcl-2 gene blocked activation of
caspase-9 and caspase-3. Processing of tau and APP was sup-
pressed, therewere reducednumbers ofNFTs anddeposits of A,
and memory performance was improved (Rohn et al., 2008).
Upstream of apoptosome formation, regulation of bcl-2 family
members is also implicated in neurodegenerative disease.Upregula-
tion of the proapoptotic bcl-2 family member Bax is observed in
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several neurodegenerative diseases (Tatton et al., 2003; Mattson,
2006). Dysregulation of Pumamay also be involved in neurodegen-
eration. Puma is an important mediator of motoneuron death in a
mouse ALS (SOD1) model (Kieran et al., 2007). Upregulation of
Puma is associated with an animal model of Parkinson’s disease
(Karunakaran et al., 2008), and is required for cell death in a cellular
modelofPD(Biswaset al., 2005). InductionofPumaexpressionalso
occurs in the striatum in a metabolic inhibition model of Hunting-
ton’s disease (Zhang et al., 2009b), and upregulation of Puma and
other BH3-only proteins may also contribute to delayed neuronal
loss following ischemia (Webster et al., 2006; Niizuma et al., 2009).
Our findings that synaptic activity can strongly suppress expres-
sion of genes encoding Puma, procaspase-9, its upstream activator
Apaf-1, and downstream effector caspase-3 suggest that active neu-
rons may be more resistant to certain aspects of caspase-associated
disease progression.Conversely, deprivationofnormalneuronal ac-
tivity as part of the disease process (such as through nerve terminal
degeneration) may result in the de-repression of these genes and
subsequently exacerbate disease progression. As well as suppressing
the apoptoticmachinery, neuronal activity also boosts neuronal an-
tioxidant defenses via a coordinated program of gene expression
changes (Papadia et al., 2008) and upregulates nuclear Ca2-
dependent pro-survival genes (Papadia et al., 2005; Zhang et al.,
2009a).One could envisage that depleted antioxidant defenses, cou-
pled with upregulated proapoptotic genes and insufficient nuclear
Ca2 signaling could all contribute to loss of neuronal function
and/or viability when neurons are deprived of activity.
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